This means that competitors of the data originator pharmaceutical producer must be prevented from obtaining the latter’s data through unfair commercial means (“misappropriation”),569 and of using it for unfair commercial advantage, such as to shorten the time and reduce the cost for reverse engineering. This leaves competitors free to either license existing data or to generate their own (such as through reverse engineering without unfair access to secret data), if the DRA so requires. In this connection, the generic producer is not obliged to submit to the DRA clinical data proving the safety and efficacy of his medicament, if he can show that the generic drug is bioequivalent to the originator product.